Pantoprazole Sodium Hydrate

来源：证券-红岸工作室10月24日，华纳药厂跌3.47%，成交额1.87亿元，换手率2.80%，总市值66.17亿元。异动分析创新药+合成生物+仿制药一致性评价+专精特新+幽门螺杆菌概念1、2024年10月1日公告，子公司上海致根医药科技有限公司是一家聚焦于 CNS 领域创新药物的研发的小分子创新药物研发公司， 公司在研的 ZG-001 是一款具有潜在国际领先优势的抗抑郁药物，目前处于临床一期接近尾声转入二期临床研究阶段。2、根据2025年半年报：生物合成技术是一项指向未来的药物合成技术，其因高收得率、高选择性、环境友好、高安全性等特点受到业界广泛推崇，但也因其涉及基因编辑技术、基因合成与组装技术、生物信息学分析技术、细胞构建技术、发酵与细胞培养技术、产品分离与纯化技术、生物与分子生物学分析检测技术等跨学科多专业的交叉需求，导致其应用的技术难点较多，技术壁垒较难穿透，技术的产业化应用推进缓慢。公司依托濒危动物药材替代组分的研发与中试技术转移，和一系列产品酶化学反应技术的产业化应用，逐步通过相关技术的研究与应用，包括基因编辑构建生物质粒，并进一步以特定质粒构建工程细胞、细菌发酵培养、产品分离纯化等和工程酶筛选、分离、固化、产业化等研究，构建起初步的生物合成特定蛋白质大分子技术的产业化平台和基于酶化学的产业化应用平台，平台技术已逐步应用于濒危动物药材ZY系列组分的制备、肾上腺素、酒石酸间羟胺、替格瑞洛、舒更葡糖钠等品种的工艺研究和产业化应用中。3、根据2022年年报，公司药品研究注册成果丰硕，为公司长足发展提供了有力支撑。报告期内，公司已获得维D钙咀嚼片、枸橼酸铋钾颗粒等2个药品注册批件；硝普钠、右布洛芬等2个原料药产品备案登记号转为“A”；甘磷酰胆碱、替格瑞洛等2个原料药产品获得韩国注册证书；吗替麦考酚酯胶囊、泮托拉唑钠肠溶片、琥珀酸亚铁片等3个产品顺利通过仿制药一致性评价。此外，2023年年初至今公司获得了替格瑞洛片、吸入用硫酸沙丁胺醇溶液、溴夫定片等3个药品注册批件。4、专精特新“小巨人”企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新小巨人企业名单。5、公司胶体果胶铋干混悬剂、胶体果胶铋胶囊、胶体酒石酸铋胶囊、枸橼酸铋钾胶囊等铋剂系列产品可治疗由幽门螺杆菌引起的相关疾病。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-1239.61万，占比0.1%，行业排名125/158，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-14.57亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入-1461.48万64.19万-859.03万-1.36亿-9778.71万主力持仓主力轻度控盘，筹码分布较为分散，主力成交额7718.45万，占总成交额的12.56%。技术面：筹码平均交易成本为56.25元该股筹码平均交易成本为56.25元，近期筹码快速出逃，建议调仓换股；目前股价靠近压力位52.08，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001年4月30日，上市日期2021年7月13日，公司主营业务涉及化学原料药、化学药制剂和中药制剂的研发、生产与销售。主营业务收入构成为：制剂产品73.19%，原料药及中间体25.22%，技术服务1.52%，植物提取物及食品0.06%，其他0.01%。华纳药厂所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：多胎概念、肝炎治疗、中药、创新药、原料药等。截至6月30日，华纳药厂股东户数7277.00，较上期增加41.85%；人均流通股18045股，较上期减少1.31%。2025年1月-6月，华纳药厂实现营业收入7.14亿元，同比减少3.37%；归母净利润7111.55万元，同比减少36.95%。分红方面，华纳药厂A股上市后累计派现2.91亿元。近三年，累计派现2.25亿元。机构持仓方面，截止2025年6月30日，华纳药厂十大流通股东中，景顺长城研究精选股票A（000688）位居第八大流通股东，持股128.82万股，为新进股东。安信医药健康股票A（010709）位居第九大流通股东，持股122.94万股，相比上期增加50.44万股。融通健康产业灵活配置混合A/B（000727）退出十大流通股东之列。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。

New Delhi: Under its monthly quality review drive, the Central Drugs Standard Control Organization ( CDSCO ) has identified 112 Not of Standard Quality (NSQ) drug samples along with a spurious sample of a cough syrup. Making the announcement, the Union Health Ministry in a note sated that, of the total 112 NSQ samples, Central Drugs Laboratories have identified 52, while the remaining 60 were flagged by State Drugs Testing Laboratories. The NSQ list of September includes several common medicines such as Paracetamol, Pantoprazole,, Multivitamin supplements and several other common drugs. Meanwhile, as per the CDSCO alert the drug sample flagged as spurious by the state drug testing laboratory in Chhattisgarh is of a dry cough syrup ‘Besto-Cof’ Several e-pharmacy platforms have listed the drug as a formulation of Phenylephrine, Chlorpheniramine Maleate and Dextromethorphan Hydrobromide marketed by ‘ BestoChem Formulations India Ltd. ’ “The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and the same is a spurious drug.” the alert, suggests. According to CDSCO, the product is purported to be spurious, subject to outcome of an ongoing investigation into the matter. Under the Drugs and Cosmetic act of 1940, a drug is deemed as spurious if it is manufactured under a name which belongs to another drug and resembles in a manner likely to deceive consumers. The identification of a spurious cough syrup from the batches collected in September coincides with a tragic incident in Madhya Pradesh (an adjoining state to Chhattisgarh) where at least 24 children died after consuming a cough syrup brand Coldrif., later found found to contain 48.6 per cent Diethylene Glycol (DEG), a toxic solvent whose permissible limit in pharmacopeial formulations is only 0.1 percent. In October, two more brands—Respifresh TR and ReLife—were identified as contaminated with Diethylene Glycol (DEG) beyond the permissible limit; however, they were not linked to any of the reported casualties in MP. Following a official communication from the CDSCO, last week the World Health Organisation (WHO) had issued a global alert for three brands–Coldrif manufactured by Tamil Nadu-based Sresan Pharmaceuticals, Respifresh TR by Gujarat-based Rednex Pharmaceuticals and ReLife by Shape Pharma. Accordion to a PTI report the Union Health Ministry is also mulling to bring a new law replacing the Drugs and Cosmetics act of 1940 to arm the central body with more powers such as, “to take immediate action against manufacturers of fake or substandard medicines.” Meanwhile, the central regulator on its part has also undertaken several measures including mandatory testing of raw material used for producing formulations, online monitoring of high risk solvents along with conducting risk-based inspections at serval pharma clusters. By Online Bureau ,